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Abstract
Background—Seasonal influenza vaccination has been routinely recommended for adults with 
high-risk conditions. The Advisory Committee on Immunization Practices recommended that 
persons 25 to 64 years of age with high-risk conditions be one of the initial target groups to 
receive H1N1 vaccination during the 2009-2010 season.
Methods—We used data from the 2009-2010 Behavioral Risk Factor Surveillance System 
survey. Vaccination levels of H1N1 and seasonal influenza vaccination among respondents 25 to 
64 years with high-risk conditions were assessed. Multivariable logistic regression models were 
performed to identify factors independently associated with vaccination.
Results—Overall, 24.8% of adults 25 to 64 years of age were identified to have high-risk 
conditions. Among adults 25 to 64 years of age with high-risk conditions, H1N1 and seasonal 
vaccination coverage were 26.3% and 47.6%, respectively. Characteristics independently 
associated with an increased likelihood of H1N1 vaccination were as follows: higher age; Hispanic 
race/ethnicity; medical insurance; ability to see a doctor if needed; having a primary doctor; a 
routine checkup in the previous year; not being a current smoker; and having high-risk conditions 
other than asthma, diabetes, and heart disease. Characteristics independently associated with 
seasonal influenza vaccination were similar compared with factors associated with H1N1 
vaccination.
Conclusion—Immunization programs should work with provider organizations to review efforts 
made to reach adults with high-risk conditions during the recent pandemic and assess how and 
where they can increase vaccination coverage during future pandemics.
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Annual epidemics of influenza in the United States occur typically during the late fall 
through early spring. During these annual epidemics, rates of serious illness and death are 
higher among those who have medical conditions that place them at increased risk for 
complications from influenza.1 Vaccination of persons with high-risk conditions is a key 
public health strategy preventing influenza-related morbidity and mortality in the United 
States.1 Prevention of illness through comprehensive vaccination programs is far more cost-
effective than case management and other outbreak control measures.1 Optimal use of 
vaccination strategies can not only reduce influenza-related morbidity and mortality but can 
also minimize missed work days because of illness.1 Persons with high-risk conditions are at 
increased risk of complications from influenza infection, and annual influenza vaccination 
was recommended for persons with high-risk conditions by public health services as early as 
1960.1,2
In April 2009, a H1N1 virus was determined to be the cause of respiratory illness that spread 
to every region in the United States, throughout North America, and was identified in many 
other areas of world. Influenza morbidity caused by the H1N1 pandemic remained above 
seasonal baselines throughout spring and summer 2009 and was the cause of the first 
pandemic since 1968.1, 3 During the H1N1 pandemic, adults <65 years of age were at higher 
risk for influenza-related complications, particularly those who had underlying medical 
conditions, compared with typical influenza seasons.1,4-6 In July 2009, the Advisory 
Committee on Immunization Practices (ACIP) issued recommendations regarding the use of 
a new monovalent vaccine for protection from infection with the 2009 influenza A (H1N1) 
virus.3 Persons 25 to 64 years of age with high-risk conditions were 1 of 5 initial target 
groups recommended to receive the influenza A (H1N1) 2009 monovalent vaccine (H1N1 
vaccine) when it became available in October 2009.3
Questions were added to the ongoing Behavioral Risk Factor Surveillance System (BRFSS) 
survey as part of an influenza supplemental survey during the 2009-2010 influenza season to 
assess H1N1 and seasonal influenza vaccination coverage in the United States. The objective 
of this study was to address and examine the following questions: (1) What was the national 
H1N1 and seasonal influenza vaccination coverage among adults with high-risk conditions? 
(2) Did vaccination coverage vary by specific types of high-risk conditions? (3) What was 
state-specific vaccination coverage for adults with high-risk conditions? (4) What factors 
were significantly associated with influenza vaccination among adults with high-risk 
conditions? Results from this analysis may help immunization programs and provider 
organizations review specific activities that were implemented to ensure vaccination of 
adults with high-risk conditions and prepare for future pandemics.
Methods
Data from the 2009-2010 BRFSS influenza supplemental survey were used for this analysis. 
The BRFSS is a continuous, population-based telephone survey coordinated by state health 
departments in collaboration with the Centers for Disease Control and Prevention (CDC). 
The BRFSS collects information from noninstitutionalized adults ≥18 years of age. The 
objective of the BRFSS is to collect uniform, state-specific data on self-reported preventive 
health practices and risk behaviors that are linked to preventable infectious diseases, chronic 
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diseases, and injuries. Individuals are selected randomly using a multistage cluster design. 
Data are weighted by age, sex, and, in some states, race/ethnicity, to reflect each area's 
estimated adult population.7
The BRFSS Influenza Supplemental Survey began in October 2009 in 49 states, the District 
of Columbia, and 2 territories. Questions were included to collect H1N1 vaccination 
information. Those major questions included “There were two ways to get the H1N1 flu 
vaccination, one is a shot in the arm and the other is a spray, mist or drop in the nose. Since 
September, 2009, have you been vaccinated either way for the H1N1 flu?” and “During what 
month did you receive your H1N1 flu vaccine?” Questions regarding seasonal influenza 
vaccination included “Now I will ask you questions about seasonal flu. A flu shot is an 
influenza vaccine injected into your arm. During the past 12 months, have you had a 
seasonal flu shot?” and “During what month did you receive your most recent seasonal flu 
shot?” “The seasonal flu vaccine sprayed in the nose is also called FluMist. During the past 
12 months, have you had a seasonal flu vaccine that was sprayed in your nose?” and “During 
what month did you receive your most recent seasonal flu vaccine that was sprayed in your 
nose?” Regarding high-risk conditions, respondents were asked “Have you ever been told by 
a doctor, nurse, or other health professional that you had asthma?”, “Do you still have 
asthma?”, “Have you ever been told by a doctor that you have diabetes?”, “Have you ever 
been told by a doctor that you had a heart attack, also called a myocardial infarction?”, 
“Have you ever been told by a doctor that you had angina or coronary heart disease?”, “Has 
a doctor, nurse, or other health professional ever said that you have lung problems, other 
than asthma, kidney problems, anemia, including sickle cell or a weakened immune system 
caused by a chronic illness or by medicines taken for a chronic illness?”, and “Do you still 
have (this/any of these) problem(s)?”
We defined high-risk persons as individuals who self-reported 1 or more of the following: 
diabetes, asthma, myocardial infarction, coronary heart disease, lung problems other than 
asthma, kidney problems, anemia (including sickle cell), and a weakened immune system 
caused by illness or medicines.
Variables included in the analyses were demographic: age group (25-49 years, 50-64 years), 
race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, other), education (less 
than high school education, high school graduate, higher than high school graduate), 
employment status (employed, unemployed), household income (<$20,000, $20,000-
$49,999, $50,000-$74,999, ≥$75,000), marital status (married, widowed/divorced/separated, 
never married), and metropolitan statistical area (MSA) (in MSA, not in MSA); health status 
(perceived health status [excellent/very good, good, fair, poor]), asthma status (yes, no), 
diabetes status (yes, no), heart diseases status (yes, no), and status of high-risk conditions 
(yes, no); access to care (medical insurance status [insured, uninsured]), needed to see a 
doctor in the previous year but could not (yes, no), having a primary doctor (yes, no), and 
interval since last routine checkup (<1year, ≥1 year); behavioral risk factors (activity 
limitations [yes, no]); and smoking status (current smoker, former smoker, never smoker).
The Council of American Survey Research Organizations response rate is the product of 3 
other rates: the resolution rate, which is the proportion of telephone numbers that can be 
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identified as either for a business or residence; the screening rate, which is the proportion of 
qualified households that complete the screening process; and the cooperation rate, which is 
the proportion of contacted eligible households for which a completed interview is obtained. 
For the 2009-2010 BRFSS influenza supplemental survey, the median Council of American 
Survey Research Organizations state response and cooperation rates were 54% (range: 
52%-62%) and 76% (range: 74%-80%), respectively.
SUDAAN (Software for the statistical analysis of correlated data, Research Triangle 
Institute, Research Triangle Park, NC) was used to calculate point estimates and 95% 
confidence intervals (CIs). To maximize precision and validity for national and state-specific 
H1N1 vaccination coverage, we analyzed data from interviews conducted during November 
2009 through June 2010 to estimate the cumulative proportion of persons vaccinated during 
October 2009 through May 2010 using the Kaplan-Meier survival analysis procedure. For 
national and state-specific 2009-2010 seasonal influenza vaccination coverage, we analyzed 
data from interviews conducted during October 2009 through June 2010 to estimate the 
cumulative proportion of persons vaccinated during August 2009 through May 2010 using 
the Kaplan-Meier survival analysis procedure. Multivariable logistic regression models 
restricted to individuals interviewed during March through June 2010 were performed to 
determine adjusted prevalence ratio and identify factors independently associated with 
vaccination. Respondents who reported unknown or refused influenza vaccination status 
were excluded from this analysis (H1N1 vaccination = 7%, seasonal influenza vaccination = 
3%). Vaccination status was imputed for individuals who said they received vaccination but 
did not report their month and year of vaccination (H1N1 vaccination = 3%, and seasonal 
influenza vaccination = 5%). Variables were determined to be significant at P < .05.
Results
A total of 182,242 individuals 25 to 64 years of age was included in the analysis. Of the 
182,242 adults aged 25 to 64 years, 24.8% reported having high-risk conditions. 
Demographic characteristics of the study population are given in Table 1. Distributions on 
each characteristic differed significantly among adults with high-risk conditions compared 
with adults without high-risk conditions. Adults with high-risk conditions were more likely 
to be higher age, unemployed, lower income, having a primary doctor, a routine checkup in 
the previous year, and being current smokers compared with adults without high-risk 
conditions (Table 1).
Overall, among adults 25 to 64 years of age with high-risk conditions, H1N1 and seasonal 
vaccination coverage estimates were 26.3% (95% CI: 25.4-27.3) and 47.6% (95% CI: 
45.7-49.6), respectively, significantly higher than those without high-risk conditions (18.5% 
and 31.8%, respectively). Across the majority of subgroups, H1N1 and seasonal influenza 
vaccination coverage were significantly higher among adults with high-risk conditions 
compared with those without high-risk conditions (Table 2, Table 3).
Among adults aged 25 to 49 years with high-risk conditions, H1N1 and seasonal influenza 
vaccination coverage estimates were 23.2%(95% CI: 21.8-24.8) and 37.5%(95% CI: 
36.0-39.0), respectively, compared with 18.4% (95% CI: 17.7-19.0) and 28.6% (95% CI: 
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27.9-29.3), respectively, among those aged 25 to 49 years without high-risk conditions. 
Among adults aged 50 to 64 years with high-risk conditions, H1N1 and seasonal influenza 
vaccination coverage was 29.6% (95% CI: 28.4-30.8) and 54.3% (95% CI: 53.1-55.6), 
respectively, compared with 19.0% (95% CI: 18.3-19.7) and 39.2% (95% CI: 38.4-40.0), 
respectively, among those aged 50 to 64 years without high-risk conditions (Table 2, Table 
3).
Among adults aged 25 to 64 years, H1N1 vaccination coverage was 26.1% for adults with 
asthma, 29.0% for adults with diabetes, 26.5% for adults with heart disease, and 28.8% for 
adults with other high-risk conditions. Among adults with high-risk conditions, H1N1 
vaccination coverage was significantly higher among adults with diabetes and adults with 
other high-risk conditions compared with adults without those conditions. Seasonal 
influenza vaccination coverage was 44.8% for adults with asthma, 52.4% for adults with 
diabetes, 47.6% for adults with heart disease, and 46.7% for adults with other high-risk 
conditions. Among adults with high-risk conditions, seasonal influenza vaccination coverage 
was significantly higher among adults with diabetes compared with adults without diabetes 
(Table 2, Table 3).
In bivariable analysis, among adults aged 25 to 64 years with high-risk conditions, H1N1 
vaccination coverage was significantly lower for non-Hispanic blacks compared with non-
Hispanic whites. Coverage was also higher among persons who reported having higher 
education, having medical insurance, access to a primary care physician, and not being a 
current smoker. Additionally, persons who needed to see a doctor but could not and those 
who had not had a routine checkup within a year were less likely to be vaccinated (Table 2). 
Factors associated with seasonal influenza vaccination were similar compared with factors 
associated with H1N1 vaccination; however, for race/ethnicity, Hispanics had lower 
coverage than non-Hispanic whites (Table 3).
In multivariable analysis, most factors that were significantly associated with H1N1 
vaccination in the bivariable analysis were still significant in the multivariable analysis 
except for education and income. Most factors that were significantly associated with 
seasonal influenza vaccination in the bivariable analysis were still significant in the 
multivariable analysis except for marital status (Table 2, Table 3).
Overall, state-specific H1N1 vaccination coverage among persons aged 25 to 64 years with 
high-risk conditions ranged from 15.0% (95% CI: 11.7-19.2) in Mississippi to 44.0% (95% 
CI: 36.5-52.4) in Massachusetts with a median of 27.6% across all states. Vaccination 
coverage was below 20% in 4 states—Mississippi, Florida, Alabama, and South Carolina— 
and coverage was above 40% in 4 states— Maine, Hawaii, Massachusetts, and Minnesota. 
Vaccination coverage ranged from 9.9% (95% CI: 6.4-15.1) in Mississippi to 46.1% (95% 
CI: 33.3-61.2) in Maine with a state median of 27.2% for adults with asthma, 15.2% (95% 
CI: 10.8-21.0) in Mississippi to 64.2% (95% CI: 43.7-84.1) in Massachusetts with a median 
of 30.7% for adults with diabetes, 12.8% (95% CI: 9.9-16.6) in Florida to 52.1% (95% CI: 
39.6-65.8) in South Dakota with a median of 26.8% for adults with heart diseases, and 
17.9% (95% CI: 11.6-27.0) in Mississippi to 62.8% (95% CI: 46.3-79.3) in Hawaii with a 
median of 30.9% for adults with other high-risk conditions.
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State-specific seasonal influenza vaccination coverage among persons aged 25 to 64 years 
with high-risk conditions ranged from 34.9% (95% CI: 31.2-38.9) in Florida to 62.9% (95% 
CI: 55.6-70.3) in Minnesota with a median of 48.8% across all states. Vaccination coverage 
was below 40% in 3 states—Florida, Nevada, and Arizona— and coverage was above 60% 
in 2 states—Nebraska and Minnesota. Vaccination coverage ranged from 35.5% in Arizona 
to 60.6% in Nebraska with a state median of 46.6% for adults with asthma, 42.3% in 
Georgia to 89.9% in Alaska with a median of 54.8% for adults with diabetes, 34.9% in 
Alaska to 73.7% in South Dakota with a median of 48.6% for adults with heart diseases, and 
36.4% in Florida to 69.2% in Minnesota with a median of 47.0% for adults with other high-
risk conditions. Among persons aged 25 to 64 years with high-risk conditions, the state-
specific H1N1 vaccination coverage was highly correlated with seasonal influenza 
vaccination coverage (r = 0.8). (Note: state-specific H1N1 and seasonal vaccination 
coverage are not shown in tables but are available if requested by readers).
Discussion
This report assessed H1N1 and seasonal influenza vaccination in the 2009-2010 season by 
specific types of high-risk conditions; previous reports have assessed seasonal influenza 
vaccination coverage among persons with high-risk conditions for prior seasons.8-15 We 
found that H1N1 and seasonal influenza vaccination coverage was only 26.3% and 47.6%, 
respectively, among adults with high-risk conditions. Vaccination coverage varied by state 
and specific types of high-risk conditions.
Overall, H1N1 vaccination coverage among adults aged 25 to 64 years with high-risk 
conditions was lower (range 26% to 29%) than the coverage among children 6 months to 17 
years (37%).16,17 Reasons for this might include a lesser emphasis on vaccination of this 
population compared with children; lack of preexisting relationship of state immunization 
programs with providers who serve adults at high risk; difficulty in implementing a risk-
condition-based recommendation for persons in this high-risk group; many high-risk 
patients do not consider themselves as high risk, which means targeted messages are not 
getting through to them; historically low seasonal influenza vaccination coverage in this 
population1,8-15,18; and the vaccines for children program (a federally funded program that 
provides vaccines at no cost to children aged ≤18 years who might not otherwise be 
vaccinated because of inability to pay) might help improve vaccination coverage among 
children.19,20 Several ongoing programs or disease-related professional organizations have 
put in great efforts to improve influenza vaccination among persons with high-risk 
conditions.21-24 The Diabetes Quality Improvement Project, a collaborative effort between 
public and private organizations to improve preventive care for persons with diabetes, has 
been ongoing.21,22 The National Asthma Education and Prevention Program panel identified 
influenza vaccination as one of several “key clinical activities that should be considered as 
essential for quality asthma care.”23 The American Heart Association/American College of 
Cardiology together with other heart diseases organizations recommended influenza 
vaccination as secondary prevention for cardiovascular disease.24 Those ongoing activities 
may help improve vaccination coverage among persons with high-risk conditions.
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Vaccine supply and availability may contribute to the low coverage. First, demand for 
vaccination and initial supply and distribution of vaccines may vary considerably across 
geographic areas possibly related to timing of the H1N1 epidemic curve and thus may affect 
vaccination coverage and contribute to variation by state.3 The cost of the H1N1 vaccine was 
paid by the federal government and distributed free of charge in partnership with state and 
local health departments. Available vaccine supplies were allocated to states proportional to 
their total populations and shipped to public and private provider vaccination sites 
determined by the states. States developed implementation strategies in accordance with 
ACIP recommendations for the initial target groups,3 specifying vaccine distribution by 
provider type in consideration of local supply and demand or other factors. In addition, even 
though initial doses of H1N1 vaccine became available at the beginning of October 2009, 
vaccine supply was limited until early 2010.25-29
State-specific H1N1 vaccination coverage among adults with high-risk conditions varied 
widely. One of the possible reasons that may contribute to wide variability in coverage 
include the following: epidemic activity had virtually declined or disappeared in many 
southern states when vaccine became available, whereas it was still ongoing in many 
northern states, and H1N1 vaccines became available just before the main epidemic 
developed in a few Northeast states.25-30 In addition, wide variability in H1N1 vaccination 
coverage may be due to variations in state-specific pandemic planning: states that were well 
prepared for a pandemic may have found it easier to implement vaccination programs on 
very short notice.31 Wide variability in state-specific seasonal influenza vaccination 
coverage may suggest that certain factors that differ among states (eg, medical care delivery 
infrastructure, population norms, and effectiveness of state and local immunization 
programs) might explain at least part of the state-level variation in vaccination levels.15 ,16
Non-Hispanic blacks had lower H1N1 vaccination coverage than non-Hispanic whites, 
which was similar to seasonal (trivalent) influenza vaccination coverage from this study and 
several previous studies.8-15 Age was associated with vaccination among adults aged 25 to 
64 years with high-risk conditions. Our study found that coverage among adults aged 50 to 
64 years were significantly higher than those aged 25 to 49 years, and this result remained 
the same after controlling the other demographic and access to care variables. As people age, 
they become more likely to acquire high-risk conditions. Health care providers may be more 
likely to recommend vaccination to high-risk persons aged 50 to 64 years because of a 
perception of greater risk from complications of influenza infections compared with younger 
persons aged 25 to 49 years.32
We found that vaccination coverage among persons who have medical insurance, have a 
regular physician, and have visited a physician for routine checkup within a year (past 12 
months) was significantly higher than those who did not, and the significant difference 
remained after controlling for other variables. Physician contacts play an important role in 
vaccination uptake.9,12,13,33 Persons with high-risk conditions may have more frequent 
contacts with their health care providers. Routine physician visits can provide important 
opportunities for providers to vaccinate persons with high-risk conditions to improve usual 
seasonal (trivalent) vaccination coverage and vaccination coverage in possible future 
pandemics.
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Lack of awareness of the federal vaccination recommendation for H1N1 vaccination among 
the general public may have also affected vaccination coverage. Despite comprehensive 
media coverage in the wake of the H1N1 pandemic, awareness of federal influenza 
vaccination recommendations among specifically recommended adults was low. One study 
showed that only 29.5% of recommended adults correctly reported being in the target groups 
recommended to receive H1N1 vaccination.34 Awareness of the federal vaccination 
recommendation for H1N1 vaccination among persons with high-risk conditions was not 
reported; however, one study showed that awareness was slightly higher among 
recommended adults with a recent provider visit (32.2%), which may indicate that those 
persons have high-risk conditions.34
The findings in this report are subject to several limitations. First, BRFSS was a landline, 
telephone-based survey until January 2011 so excluded not only persons without telephones 
but also those with only cellular phones, which may bias influenza vaccination coverage 
estimates.35 Second, self-reported vaccination status is subject to respondents' recall and was 
not validated with medical records. No studies have evaluated the validity of self-reported of 
influenza vaccination among adults aged 25 to 64 years with high-risk conditions. However, 
self-reported seasonal (trivalent) influenza vaccination status has been shown to have 
relatively high agreement with medical records among older adults.36-40 Finally, persons 
also might have confused receipt of H1N1 vaccination with seasonal influenza vaccination.
The 2009-2010 seasonal influenza vaccination coverage among adults with high-risk 
conditions is significantly higher than H1N1 vaccination coverage; however, there were 
many differences in the timing and distribution of the seasonal and H1N1 vaccines.16,25-29 
Variation in vaccination coverage observed among states suggests that vaccination coverage 
could have been improved. Further study of state vaccination programs to understand 
reasons for variations in state-level coverage and identify program factors associated with 
high vaccination coverage among states is important for improving state-level seasonal 
influenza vaccination coverage and applying these lessons learned for potential future 
influenza pandemics. Efforts are needed to increase influenza vaccination among 
populations with lower vaccination coverage.41 The recommendation for influenza 
vaccination during the 2010-2011 season was expanded to vaccinate all persons ≥ 6 months 
of age; however, the ACIP continued to emphasize that provision of routine annual influenza 
vaccination to groups at higher risk for influenza infection or complications should be a 
focus of vaccination efforts as providers and programs transition to routinely vaccinating all 
persons ≥6 months of age.1 Continued efforts are needed to increase vaccination coverage 
among persons with high-risk conditions. Federal, state, and local governments and 
community partners should collaborate to increase implementation of culturally appropriate 
and evidence-based interventions to increase vaccination coverage among persons at risk for 
complications from influenza infection. Providers should consider each office or emergency 
room visit a potential opportunity to vaccinate persons with high-risk conditions.
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Table 1
Selected characteristics among persons aged 25 to 64 years with high-risk conditions 
(BRFSS 2010)*
All states combined, %
Persons with high-risk conditions (n = 50,242)† Persons without high-risk conditions (n = 132,000)
Total 24.8 75.2
Age, yr
 25-49 50.6 69.9‡
 50-64 49.4 30.1
Sex
 Male 43.7 49.3‡
 Female 56.3 50.7
Race/ethnicity
 White, non-Hispanic 65.0 68.3‡
 Black, non-Hispanic 14.3 10.0
 Hispanic 12.4 14.0
 Other 8.3 7.7
Education level
 Less than high school 13.7 9.4‡
 High school graduate 34.3 31.0
 More than high school graduate 52.0 59.6
Employment
 Employed 51.3 71.7‡
 Unemployed 48.7 28.3
Income, $
 <20,000 25.8 13.4‡
 20,000-49,999 31.3 29.8
 50,000-74,999 32.7 17.2
 75,000+ 10.2 34.2
Marital status
 Married 58.5 69.1‡
 Widowed/divorced/separated 25.7 15.5
 Never married 15.8 15.4
Perceived health
 Excellent/very good 26.8 61.4‡
 Good 33.3 29.2
 Fair 25.4 7.8
 Poor 14.5 1.6
Insurance status
 Yes 82.1 81.1‡
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All states combined, %
Persons with high-risk conditions (n = 50,242)† Persons without high-risk conditions (n = 132,000)
 No 17.9 18.9
Need to see a doctor but could not
 Yes 26.0 16.2‡
 No 74.0 83.8
Primary doctor
 Yes 86.6 77.0‡
 No 13.4 23.0
Activity limitation
 Yes 42.3 13.9‡
 No 57.7 86.1
Time since last checkup
 <1 yr 73.8 61.9‡
 ≥1 yr 26.2 38.1
Smoke status
 Current smoker 26.9 20.7‡
 Former smoker 27.2 22.2
 Never smoker 45.9 57.1
Influenza vaccination
 H1N1 and seasonal 15.7 10.7‡
 H1N1 only 4.2 4.0
 Seasonal only 26.4 18.4
 Neither 53.7 66.9
MSA
 In MSA 90.9 92.0‡
 Not in a MSA 9.1 8.0
Persons with asthma
 Yes 40.1 N/A
 No 59.9 N/A
Persons with diabetes
 Yes 35.9 N/A
 No 64.1 N/A
Persons with heart diseases
 Yes 26.0 N/A
 No 74.0 N/A
Persons with other high-risk conditions§
 Yes 34.7 N/A
 No 65.3 N/A
MSA, Metropolitan Statistical Area; N/A, data are not applicable.
*
This table is based on interviews conducted October 2009 through June 2010.
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†
Influenza-related high-risk conditions included diabetes, asthma, myocardial infarction, coronary heart disease, lung problems other than asthma, 
kidney problems, anemia (including sickle cell), and a weakened immune system caused by illness or medicines.
‡Significant difference among persons with high-risk conditions and persons without high-risk conditions (by χ2 test, P < .05).
§Other high-risk conditions included lung problems other than asthma, kidney problems, anemia (including sickle cell), and a weakened immune 
system caused by illness or medicines.
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Table 2
The H1N1 vaccination coverage by demographic and access to care variables among 
persons aged 25 to 64 years with high-risk conditions and without high-risk conditions, 
2010
Demographic
H1N1 vaccination coverage Adjusted prevalence ratio*
Persons w/high-risk 
conditions† % (95% 
CI)
Persons w/o high-risk 
conditions % (95% CI)
Persons w/high-risk 
conditions % (95% 
CI)
Persons w/o high-
risk conditions % 
(95% CI)
Total 26.3 (25.4-27.3) 18.5 (18.0-19.1)‡
Age, yr
 25-49§ 23.2 (21.8-24.8) 18.4 (17.7-19.0)‡ Referent Referent
 50-64 29.6 (28.4-30.8)‖ 19.0 (18.3-19.7)‡ 1.2 (1.0-1.3)‖ 1.0 (0.9-1.0)
Sex
 Male§ 26.8 (25.2-28.5) 16.8 (16.1-17.6)‡ Referent Referent
 Female 26.0 (24.9-27.1) 20.2 (19.6-20.9)‡,‖ 1.0 (0.9-1.1) 1.1 (1.1-1.2)‖
Race/ethnicity
 White, non-Hispanic§ 27.5 (26.4-28.6) 18.4 (17.9-19.0)‡ Referent Referent
 Black, non-Hispanic 21.2 (18.7-23.9)‖ 14.8 (13.1-16.6)‡,‖ 0.8 (0.7-1.0)‖ 0.7 (0.6-0.9)‖
 Hispanic 26.7 (23.6-30.2) 19.5 (17.8-21.3)‡ 1.2 (1.1-1.5)‖ 1.1 (1.0-1.2)
 Other 26.2 (22.9-30.0) 22.2 (20.2-24.4)‖ 1.0 (0.8-1.2) 1.2 (1.1-1.4)‖
Education level
 Less than high school§ 23.8 (21.2-26.7) 14.8 (13.1-16.7)‡ Referent Referent
 High school graduate 22.6 (20.9-24.4) 14.1 (13.2-15.1)‡ 0.9 (0.8-1.1) 0.9 (0.8-1.1)
 More than high school 
graduate
29.4 (28.2-30.7)‖ 21.5 (20.9-22.1)‡,‖ 1.2 (1.0-1.4) 1.2 (1.0-1.4)‖
Perceived health
 Excellent/very good§ 27.5 (25.6-29.4) 19.4 (18.8-20.1)‡ Referent Referent
 Good 24.8 (23.3-26.3) 17.3 (16.3-18.3)‡,‖ 1.0 (0.9-1.2) 1.0 (0.9-1.1)
 Fair 26.0 (24.3-27.8) 16.0 (14.4-17.9)‡,‖ 1.2 (1.0-1.3)‖ 1.1 (0.9-1.3)
 Poor 28.6 (25.7-31.7) 19.1 (15.4-23.6)‡ 1.2 (1.0-1.4) 1.3 (1.0-1.6)
Insurance status
 Yes 28.6 (27.5-29.7)‖ 20.5 (19.9-21.0)‡,‖ 1.2 (1.0-1.4)‖ 1.4 (1.2-1.6)‖
 No§ 16.6 (14.6-18.8) 10.6 (9.6-11.6)‡ Referent Referent
Need to see a doctor but could not
 Yes§ 19.0 (17.3-21.8) 12.6 (11.5-13.8)‡ Referent Referent
 No 29.0 (27.9-30.2)‖ 19.7 (19.2-20.3)‡,‖ 1.3 (1.2-1.5)‖ 1.2 (1.1-1.4)‖
Primary doctor
 Yes 28.2 (27.2-29.3)‖ 20.5 (19.9-21.0)‡,‖ 1.3 (1.1-1.7)‖ 1.2 (1.1-1.3)‖
 No§ 14.4 (12.2-17.0) 12.3 (11.2-13.4) Referent Referent
Am J Infect Control. Author manuscript; available in PMC 2018 February 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lu et al. Page 16
Demographic
H1N1 vaccination coverage Adjusted prevalence ratio*
Persons w/high-risk 
conditions† % (95% 
CI)
Persons w/o high-risk 
conditions % (95% CI)
Persons w/high-risk 
conditions % (95% 
CI)
Persons w/o high-
risk conditions % 
(95% CI)
Time since last checkup
 <1 yr 29.4 (28.3-30.6)‖ 22.4 (21.8-23.1)‡,‖ 1.3 (1.1-1.5)‖ 1.5 (1.4-1.6)‖
 ≥1 yr§ 18.5 (16.9-20.2) 12.7 (12.0-13.4)‡ Referent Referent
Smoke status
 Current smoker§ 20.9 (18.9-23.0) 12.9 (11.8-14.0)‡ Referent Referent
 Former smoker 30.4 (28.6-32.2)‖ 19.3 (18.4-20.3)‡,‖ 1.3 (1.1-1.5)‖ 1.3 (1.2-1.5)‖
 Never smoker 27.1 (25.8-28.5)‖ 20.4 (19.7-21.1)‡,‖ 1.3 (1.1-1.4)‖ 1.3 (1.1-1.4)‖
Persons with asthma
 Yes 26.1 (24.7-27.5) N/A 1.1 (1.0-1.2) N/A
 No§ 26.6 (25.3-27.9) N/A Referent N/A
Persons with diabetes
 Yes 29.0 (27.5-30.6)‖ N/A 1.1 (1.0-1.2) N/A
 No§ 24.9 (23.7-26.1) N/A Referent N/A
Persons with heart diseases
 Yes 26.5 (24.5-28.7) N/A 1.0 (0.9-1.2) N/A
 No§ 26.3 (25.3-27.4) N/A Referent N/A
Persons with other high-risk conditions¶
 Yes 28.8 (27.2-30.6)‖ N/A 1.2 (1.1-1.3)‖ N/A
 No§ 24.9 (23.8-26.1) N/A Referent N/A
MSA, Metropolitan Statistical Area; N/A, data are not applicable; w/, with; w/o, without.
NOTE. Vaccination coverage is based on interviews conducted during November 2009 through June 2010. Multivariable analysis (adjusted 
prevalence ratio) is based on interviews conducted during March through June 2010.
*Activity limitation, employment status, Metropolitan Statistical Area (MSA) status, income, and marital status were included in the multivariable 
models but not shown in the table because those variables are not significant for both models (persons with high-risk conditions and persons 
without high-risk conditions).
†
Influenza-related high-risk conditions included diabetes, asthma, myocardial infarction, coronary heart disease, lung problems other than asthma, 
kidney problems, anemia (including sickle cell), and a weakened immune system caused by illness or medicines.
‡P < .05 by χ2 test for comparisons between persons with high-risk conditions and persons without high-risk conditions.
§
Reference level.
‖P < .05 by χ2 test for comparisons within each variable with indicated reference level.
¶Other high-risk conditions included lung problems other than asthma, kidney problems, anemia (including sickle cell), and a weakened immune 
system caused by illness or medicines.
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Table 3
Seasonal influenza vaccination coverage by demographic and access to care variables 
among persons aged 25 to 64 years with high-risk conditions and without high-risk 
conditions, 2010
Demographic
Seasonal influenza vaccination coverage Adjusted prevalence ratio*
Persons w/high-risk 
conditions† % (95% CI)
Persons w/o high-risk 
conditions % (95% CI)
Persons w/high-risk 
conditions % (95% 
CI)
Persons w/o high-
risk conditions % 
(95% CI)
Total 47.6 (45.7-49.6) 31.8 (31.2-32.3)‡
Age, yr
 25-49§ 37.5 (36.0-39.0) 28.6 (27.9-29.3)‡ Referent Referent
 50-64 54.3 (53.1-55.6)‖ 39.2 (38.4-40.0)‡,‖ 1.2 (1.1-1.3)‖ 1.2 (1.2-1.3)‖
Sex
 Male§ 42.4 (40.4-44.4) 26.2 (25.2-27.2)‡ Referent Referent
 Female 44.2 (42.8-45.7) 32.7 (31.8-33.5)‡,‖ 1.1 (1.0-1.2)‖ 1.2 (1.1-1.2)‖
Race/ethnicity
 White, non-Hispanic§ 48.3 (47.2-49.4) 34.0 (33.5-34.6)‡ Referent Referent
 Black, non-Hispanic 39.6 (36.8-42.4)‖ 25.9 (23.8-28.1)‡,‖ 0.9 (0.8-1.0)‖ 0.8 (0.7-0.9)‖
 Hispanic 41.4 (37.9-45.0)‖ 24.1 (22.5-25.7)‡,‖ 1.1 (1.0-1.2) 0.9 (0.8-1.0)‖
 Other 43.6 (38.9-48.6) 33.4 (31.3-35.6)‡ 0.9 (0.8-1.0) 1.0 (0.9-1.1)
Education level
 Less than high school§ 38.5 (35.8-41.3) 18.0 (16.4-19.7)‡ Referent Referent
 High school graduate 42.9 (41.1-44.7) 26.1 (25.1-27.1)‡,‖ 1.0 (0.9-1.2) 1.2 (1.0-1.4)‖
 More than high school 
graduate
49.7 (48.3-51.1)‖ 36.9 (36.3-37.6)‡,‖ 1.1 (1.0-1.3)‖ 1.4 (1.2-1.6)‖
Employment
 Employed 46.9 (45.5-48.4) 33.5 (32.9-34.1)‡,‖ 1.0 (1.0-1.1) 1.1 (1.1-1.2)‖
 Unemployed§ 44.7 (43.3-46.2) 27.5 (26.4-28.5)‡ Referent Referent
Income, $
 <20,000§ 40.0 (37.8-42.3) 19.3 (18.0-20.7)‡ Referent Referent
 20,000-49,999 44.5 (42.8-46.3)‖ 27.3 (26.4-28.4)‡,‖ 1.1 (1.0-1.2) 1.1 (1.0-1.2)
 50,000-74,999 49.6 (46.8-52.4)‖ 34.5 (33.3-35.8)‡,‖ 1.1 (0.9-1.2) 1.1 (0.9-1.2)
 75,000+ 53.4 (51.4-55.4)‖ 40.5 (39.5-41.5)‡,‖ 1.2 (1.0-1.3)‖ 1.2 (1.1-1.3)‖
Insurance status
 Yes 50.1 (49.0-51.2)‖ 35.9 (35.3-36.5)‡,‖ 1.2 (1.1-1.4)‖ 1.4 (1.3-1.6)‖
 No§ 26.5 (24.3-28.8) 14.2 (13.2-15.2)‡ Referent Referent
Need to see a doctor but could not
 Yes§ 31.8 (29.9-33.7) 19.2 (18.0-20.4)‡ Referent Referent
 No 50.7 (49.6-51.9)‖ 34.2 (33.7-34.8)‡,‖ 1.3 (1.2-1.4)‖ 1.2 (1.1-1.3)‖
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Demographic
Seasonal influenza vaccination coverage Adjusted prevalence ratio*
Persons w/high-risk 
conditions† % (95% CI)
Persons w/o high-risk 
conditions % (95% CI)
Persons w/high-risk 
conditions % (95% 
CI)
Persons w/o high-
risk conditions % 
(95% CI)
Primary doctor
 Yes 49.5 (48.5-50.6)‖ 36.4 (35.9-37.1)‡,‖ 1.4 (1.2-1.6)‖ 1.4 (1.3-1.5)‖
 No§ 21.7 (19.3-24.3) 16.2 (15.2-17.3) Referent Referent
Activity limitation
 Yes 48.8 (47.3-50.4)‖ 33.3 (31.9-34.7)‡,‖ 1.1 (1.1-1.2)‖ 1.1 (1.0-1.2)‖
 No§ 43.6 (42.3-44.9) 31.6 (31.0-32.1)‡ Referent Referent
Time since last checkup
 <1 yr 51.7 (50.5-52.9)‖ 38.9 (38.1-39.6)‡,‖ 1.3 (1.2-1.4)‖ 1.4 (1.3-1.5)‖
 ≥1 yr§ 29.7 (28.0-31.5) 21.1 (20.4-21.9)‡ Referent Referent
Smoke status
 Current smoker§ 36.4 (34.6-38.3) 22.6 (21.4-23.9)‡ Referent Referent
 Former smoker 52.8 (51.0-54.7)‖ 34.6 (33.5-35.6)‡,‖ 1.2 (1.1-1.3)‖ 1.2 (1.1-1.3)‖
 Never smoker 47.2 (45.6-48.7)‖ 34.2 (33.5-34.9)‡,‖ 1.2 (1.1-1.3)‖ 1.2 (1.1-1.3)‖
Persons with asthma
 Yes 44.8 (43.2-46.4) N/A 1.1 (1.0-1.1) N/A
 No§ 46.6 (45.3-47.9) N/A Referent N/A
Persons with diabetes
 Yes 52.4 (50.7-54.1)‖ N/A 1.2 (1.1-1.2)‖ N/A
 No§ 42.1 (40.9-43.4) N/A Referent N/A
Persons with heart diseases
 Yes 47.6 (45.7-49.6) N/A 1.0 (1.0-1.1) N/A
 No§ 45.4 (44.2-46.6) N/A Referent N/A
Persons with other high-risk conditions¶
 Yes 46.7 (44.9-48.6) N/A 1.0 (1.0-1.1) N/A
 No§ 45.2 (43.9-46.4) N/A Referent N/A
N/A, data are not applicable; w/, with; w/o, without.
NOTE. Vaccination coverage is based on interviews conducted during October 2009 through June 2010. Multivariable analysis (adjusted 
prevalence ratio) is based on interviews conducted during March through June 2010.
*
Marital status, perceived health status and Metropolitan Statistical Area (MSA) status were included in the multivariable models but not shown in 
the table because those variables are not significant for both models (persons with high-risk conditions and persons without high-risk conditions).
†
Influenza-related high-risk conditions included diabetes, asthma, myocardial infarction, coronary heart disease, lung problems other than asthma, 
kidney problems, anemia (including sickle cell), and a weakened immune system caused by illness or medicines.
‡P < .05 by χ2 test for comparisons between persons with high-risk conditions and persons without high-risk conditions.
§
Reference level.
‖P < .05 by χ2 test for comparisons within each variable with indicated reference level.
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¶Other high-risk conditions included lung problems other than asthma, kidney problems, anemia (including sickle cell), and a weakened immune 
system caused by illness or medicines.
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